Source-grounded facts extracted from PROCEPT BioRobotics Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PROCEPT BioRobotics Corp shareholders approved Advisory approval of named executive officer compensation at the 2026-06-09 meeting.
“Proposal 3 in the Proxy Statement, a proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, was approved by the following vote: Votes For Votes Withheld Abstentions Broker Non-Votes 26,984,867 9,924,704 45,735 10,418,057”
PROCEPT BioRobotics Corp shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-06-09 meeting.
“Proposal 2 in the Proxy Statement, a proposal to ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, was approved by the following vote: Votes For Votes Withheld Abstentions 47,328,539 21,691 23,133”
PROCEPT BioRobotics Corp shareholders approved Election of Nominees for Director at the 2026-06-09 meeting.
“Name of Nominee Votes For Votes Withheld Broker Non-Votes Antal Desai 28,444,121 8,511,185 10,418,057 Mary Garrett 29,150,610 7,804,696 10,418,057 Frederic Moll, M.D. 36,455,610 499,696 10,418,057”
PROCEPT BioRobotics Corp reported the quarter ended March 31, 2026 results: revenue $83.1 million, net income Net loss was $31.6 million. Guidance reaffirmed.
“accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing." Wood continued: “Aquablation® users completed approximately 12,200 U.S. procedures in the first quarter of”
Thomas M. Prescott was appointed as Chairperson of the Board at PROCEPT BioRobotics Corp.
“On July 18, 2024, the Board appointed Mr. Thomas M. Prescott as a new member of the Board and as the chairperson of the Board, with such appointment effective July 18, 2024.”
Thomas Krummel resigned as Director at PROCEPT BioRobotics Corp.
“On July 18, 2024, D r. Thomas Krummel notified the board of directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) that he intends to resign as a member of the Board and as a member of the Compensation Committee of the Board, effective at the conclusion of the Board meeting on July 18, 2024.”
PROCEPT BioRobotics Corp reported financial results for the quarter ended March 31, 2024.
“On May 1, 2024 , PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024 .”
Larry Wood was appointed as Director at PROCEPT BioRobotics Corp.
“the Board appointed Mr. Larry Wood as a new member of the Board and as a member of the Audit Committee of the Board, with such appointment effective April 18, 2024.”
Colby Wood resigned as Director at PROCEPT BioRobotics Corp.
“Mr. Colby Wood notified the board of directors (the "Board") of PROCEPT BioRobotics Corporation (the "Company") that he intends to resign as a member of the Board and as a member of the Audit Committee of the Board, effective at the conclusion of the Board meeting on April 18, 2024.”
PROCEPT BioRobotics Corp reported financial results for the quarter ended December 31, 2023.
“On February 27, 2024 , PROCEPT BioRobotics Corporation (the "Company") issued a press release announcing its financial results for the quarter ended December 31, 2023.”
PROCEPT BioRobotics Corp reported full year 2023 results: revenue approximately $133.5 million. Guidance raised.
“The Company projects revenue for the full year 2023 to be approximately $133.5 million, which represents 78% growth over the Company’s prior year revenue.”
PROCEPT BioRobotics Corp reported the quarter ended September 30, 2023 results: revenue $35.1 million, net income $24.6 million.
“Total revenue for the third quarter of 2023 was $35.1 million, an increase of 72% compared to the prior year period. U.S. revenue was $32.3 million, representing growth of 73% compared to the prior year period. The increase was primarily driven by increased handpiece revenue and system sales to new hospital customers. U.S. handpiece and consumable revenue for the third quarter of 2023 was $17.0 million, an increase of 113% compared to the prior year period. Third quarter of 2023 monthly utilization per account increased 6% compared to the prior year period. U.S. system revenue for the third quarter of 2023 was $13.5 million, an increase of 37% compared to the prior year period. As of September 30, 2023, the install base of AquaBeam Robotic Systems in the U.S. was 271 systems. International revenue was $2.8 million for the quarter, an increase of 62% compared to the prior year period. Gross margin for the third quarter 2023 was 54% compared to 50% in the prior year period. Gross margin”
PROCEPT BioRobotics Corp reported full year 2023 results: revenue $131 million. Guidance raised.
“The Company projects revenue for the full year 2023 to be approximately $131 million, which represents 75% growth over the Company’s prior year revenue. This compares to previous revenue guidance of $128 million.”
PROCEPT BioRobotics Corp reported quarter ended June 30, 2023 results: net income -$25.3 million.
“Total revenue for the second quarter of 2023 was $33.1 million, an increase of 98% compared to the prior year period.”
PROCEPT BioRobotics Corp shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-15 meeting.
“Proposal 3 in the Proxy Statement, an advisory vote on the frequency of future advisory votes on executive compensation, was approved at the frequency of "every one year", by the following vote: Every 1 Year Every 2 Years Every 3 Years Abstentions Broker Non-Votes 29,190,028 140,611 155,001 1,123 5,823,167”
PROCEPT BioRobotics Corp shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-06-15 meeting.
“Proposal 2 in the Proxy Statement, a proposal to ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, was approved by the following vote: Votes For Votes Withheld Abstentions 35,294,549 6,064 9,317”
PROCEPT BioRobotics Corp shareholders approved Election of Directors at the 2023-06-15 meeting.
“All of the nominees for director listed in Proposal 1 in the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 26, 2023 (the “Proxy Statement”), were elected to serve on the Company’s board of directors until the Company’s 2026 annual meeting of stockholders, or until his or her successor is duly elected or appointed, by the following vote: Name of Nominee Votes For Votes Withheld Broker Non-Votes Frederic Moll, M.D. 29,347,415 139,348 5,823,167 Antal Desai 25,382,486 4,104,277 5,823,167 Mary Garrett 25,249,292 4,237,471 5,823,167”
PROCEPT BioRobotics Corp amended First Amendment with Canadian Imperial Bank of Commerce (effective 2023-06-01).
“On June 1, 2023, PROCEPT BioRobotics Corporation (the “Company”) entered into a First Amendment (the “Amendment”) to the Loan and Security Agreement, dated as of October 6, 2022, by and between the Company and Canadian Imperial Bank of Commerce (the “Existing Loan Agreement” and including the Amendment, the “Loan Agreement”).”
PROCEPT BioRobotics Corp reported full year 2023 results: revenue $128 million. Guidance raised.
“The Company projects revenue for the full year 2023 to be $128 million, which represents 71% growth over the Company’s prior year revenue.”
PROCEPT BioRobotics Corp reported the quarter ended March 31, 2023 results: revenue Total revenue of $24.4 million for the first quarter of 2023, net income Net loss was $28.5 million for the first quarter of 2023.
“PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2023.”
PROCEPT BioRobotics Corp reported the quarter and fiscal year ended December 31, 2022 results: revenue $74.8 million to $75.0 million.
“the fourth quarter of 2022 o Total international revenue of approximately $2.0 million for the fourth quarter of 2022 • Fiscal year 2022 revenue is expected to be approximately $74.8 million to $75.0 million, representing growth of approximately 117% compared to the prior year period The Company plans to report financial results for the fourth quarter and fiscal year”
PROCEPT BioRobotics Corp reported for the quarter ended September 30, 2022 results: revenue $20.3 million. Guidance raised.
“care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2022. Recent Highlights • Total Revenue of $20.3 million for the third quarter of 2022, an increase of 135% compared to the prior year period • U.S. system and rental revenue of $9.8 million for the third quarter of 2022, an increase”
Mary Garrett was appointed as Director at PROCEPT BioRobotics Corp.
“appointed Mary Garrett as a new Class II director of the Company”
Elisabeth Sandoval was appointed as Director at PROCEPT BioRobotics Corp.
“Effective October 21, 2021, the Board of Directors (the “Board”) of PROCEPT BioRobotics Corporation (the “Company”) increased the number of directors on the Board from eight to nine and appointed Elisabeth Sandoval as a Class I director of the Company, with such appointment taking effect immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.